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   ABSTRACT   
  Objective      To evaluate changes in baseline patient 
characteristics and entry criteria of randomised, 
controlled studies of tumour necrosis factor alpha (TNFα) 
inhibitors in rheumatoid arthritis (RA) patients.   
  Methods      A systematic literature review was performed 
using predeﬁ  ned inclusion criteria to identify randomised, 
double-blind, controlled trials that evaluated TNFα 
inhibitors in adult RA patients. Entry criteria and baseline 
clinical characteristics were evaluated over time for 
methotrexate-experienced and methotrexate-naive study 
populations. Enrolment start date for each trial was the 
time metric. The anchor time was the study with the 
earliest identiﬁ  able enrolment start date.   
  Results      44 primary publications (reporting the 
primary study endpoint) from 1993 to 2008 met the 
inclusion criteria. Enrolment start dates of August 
1993 and May 1997 were identiﬁ  ed as time anchors 
for the 37 methotrexate-experienced studies and the 
seven methotrexate-naive studies, respectively. In 
methotrexate-experienced trials, no signiﬁ  cant change 
was observed over the years included in this study in 
any inclusion criteria (including swollen joint counts and 
C-reactive protein (CRP)), but a signiﬁ  cant decrease over 
time was observed in the baseline swollen joint count, 
CRP and total Sharp or van der Heijde modiﬁ  ed Sharp 
score, but not in baseline tender joint counts. In the 
methotrexate-naive studies, signiﬁ  cant decreases over 
the years were observed in swollen joint and tender joint 
inclusion criteria, but not in baseline tender joint count, 
baseline CRP, CRP inclusion criteria or baseline total Sharp 
or van der Heijde modiﬁ  ed Sharp score.   
  Conclusion      Inclusion criteria and baseline 
characteristics of RA patients enrolled in studies of 
TNFα inhibitors have changed, with more recent trials 
enrolling cohorts with lower disease activity, especially 
in  methotrexate-experienced  trials.      
  In the early 1990s, there was a paradigm shift in 
the treatment of patients with rheumatoid arthri-
tis (RA).  1   Before this period, patients with RA 
were treated employing the ‘pyramid’ approach, in 
which non-steroidal anti-inﬂ  ammatory drugs were 
used ﬁ  rst, followed by disease-modifying antirheu-
matic drugs (DMARD) and steroids as the disease 
became more severe. The paradigm shift occurred 
when early intensive treatment was emphasised. 
Around this time, researchers also discovered the 
importance of proinﬂ   ammatory cytokines in the 
pathogenesis of RA,  2     3   which led to the ﬁ  rst thera-
peutic use of cytokine inhibition to treat patients 
with RA.  4   Several biological agents have now 
been approved by regulatory authorities in many 
countries for the treatment of patients with RA, 
including abatacept, adalimumab, certolizumab, 
etanercept, golimumab, inﬂ  iximab, rituximab and 
tocilizumab. 
  The revised approach to the treatment of patients 
with RA over the past decade, which included 
early recognition  5   and early DMARD start  6   and the 
availability of an increasing number of treatment 
options,  7     8   would be expected to result in fewer 
patients with severe disease in the population.  9     10   
Indeed, data of recent observational studies have 
suggested that the severity of RA has been decreas-
ing over time.  11     12   This has implications for clinical 
trials designed to evaluate the efﬁ  cacy and safety of 
new therapeutics,  13   however, it is not clear if this 
trend is the result of the disease becoming milder or 
the management of the disease is improving. 
  The purpose of this investigation was to evalu-
ate the changes in inclusion criteria and baseline 
characteristics of patients in randomised controlled 
  studies involving tumour necrosis factor alpha 
(TNFα) inhibitors in patients with RA. We hypoth-
esised that the disease activity of patients who par-
ticipate in these studies has decreased over time, 
reﬂ   ecting the larger trends in the population of 
patients as a whole. 
  METHODS 
  A systematic literature search was conducted 
using MEDLINE, EMBASE and the Cochrane 
Library (1988 to December 2008); clinical study 
reports (for golimumab only, these have since 
been published);  14     15   citation lists, published sys-
tematic reviews and health technology assess-
ments (1988–2008); internet sites for the US Food 
and Drug Administration, ClinicalTrials.gov and 
ClinicalStudyResults.org; and abstracts presented 
at the American College of Rheumatology (ACR) 
and the European League Against Rheumatism 
(EULAR) congresses (2004–8). 
  Databases were searched using speciﬁ  c search 
strings, which included some of the following key 
terms (synonyms and combinations): rheumatoid 
arthritis, tumour necrosis factor, tumour necrosis 
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factor receptors, anti-tumour necrosis factor,   adalimumab, 
etanercept, inﬂ  iximab, certolizumab and golimumab. Search 
ﬁ  lters were used to identify randomised controlled trials in 
MEDLINE and EMBASE. Search limits (provided by Xcenda) 
were placed in MEDLINE and EMBASE to limit the studies to 
the date ranges indicated above, English language and humans 
(from Xcenda). The last search was conducted on 13 March 
2009. Two reviewers independently inspected the titles and 
abstracts from the initial literature search to identify poten-
tially relevant publications. 
  Predeﬁ  ned inclusion criteria were applied to the results of 
the literature search in a hierarchical manner. First, only ran-
domised, double-blind, controlled trials were included that 
compared adalimumab, etanercept, certolizumab, golimumab 
or inﬂ  iximab with any other agent, including placebo or alter-
native doses of the agent, in adult patients with RA. Second, 
only trials that were published in a peer-reviewed medical 
journal, available as a complete study report (for studies 
that had completed enrolment), or abstracts with   primary 
  endpoints that had been presented at ACR or EULAR con-
gresses were included. Third, only trials with at least 4 weeks 
of follow-up and at least 25 patients were included. Single-
dose studies were included if the duration of follow-up 
exceeded 4 weeks. 
  Studies were excluded if they were designed to evalu-
ate patients with conditions other than RA (eg, juvenile RA, 
Crohn’s disease, psoriatic arthritis or ankylosing spondylitis), 
had non-randomised trial designs (eg, observational studies, 
open-label studies, non-comparative studies, case reports, sys-
tematic reviews or health technology assessments), or were pre-
clinical (animal) or phase I studies. Studies that pooled patients 
from different disease cohorts were also excluded. All publica-
tions identiﬁ  ed as potentially relevant by at least one reviewer 
were retrieved. The reviewers discussed publications that were 
 Table  1     Characteristics of primary publications for biological anti-TNFα agents   
 Reference   Anti-TNFα agent   Trial  name    Enrolment start date   Comparator   N   Patient  population 
Elliott   et al   199416 Inﬂ  iximab NA 1993 Placebo 72 MTX experienced
Moreland   et al   199717 Etanercept NA – Placebo 180 MTX experienced
Maini   et al   199818 Inﬂ  iximab NA 1994 Placebo 101 MTX experienced
Maini   et al   199919 Inﬂ  iximab ATTRACT 1997 Placebo 428 MTX experienced
Moreland   et al   199920 Etanercept NA – Placebo 234 MTX experienced
Weinblatt   et al   199921 Etanercept NA – MTX 89 MTX experienced
Bathon   et al   200022 Etanercept ERA 1997 MTX 632 MTX naive
Kavanaugh   et al   200023 Inﬂ  iximab NA 1995 Placebo 28 MTX experienced
Choy   et al   200224 Certolizumab NA – Placebo 36 MTX experienced
Furst   et al   200325 Adalimumab STAR 2000 Placebo 636 MTX experienced
van de Putte   et al   200326 Adalimumab DE007 2001 Placebo 284 MTX experienced
Weinblatt   et al   200327 Adalimumab ARMADA – MTX 271 MTX experienced
Keystone   et al   200428 Adalimumab DE019 2002 MTX 619 MTX experienced
van de Putte   et al   200429 Adalimumab DE011 2000 Placebo 544 MTX experienced
Genovese   et al   200430 Etanercept NA – Anakinra 244 MTX experienced
Keystone   et al   200431 Etanercept NA – Placebo 420 MTX experienced
Klareskog   et al   200432 Etanercept TEMPO 2000 MTX 652 MTX experienced
Lan   et al   200433 Etanercept NA 2000 Placebo 58 MTX experienced
St. Clair   et al   200434 Inﬂ  iximab ASPIRE 2000 MTX 1004 MTX naive
Johnsen   et al   200635 Etanercept NA 1999 Etanercept 77 MTX experienced
Abe   et al   200636 Inﬂ  iximab NA 2000 Placebo 147 MTX experienced
Leirisalo-Repo   et al   200637 Inﬂ  iximab NEO-RACO 2005 Placebo 99 MTX experienced
Westhovens   et al   200638 Inﬂ  iximab START 2001 Placebo 1082 MTX experienced
Zhang   et al   200639 Inﬂ  iximab NA 2003 Placebo 173 MTX experienced
Breedveld   et al   200640 Adalimumab PREMIER 2001 MTX 799 MTX naive
Kim   et al   200741 Adalimumab NA 2003 MTX 128 MTX experienced
Weisman   et al   200742 Etanercept NA 2000 Placebo 535 MTX experienced
Zhou   et al   200743 Golimumab NA 2001 Placebo 36 MTX experienced
Durez   et al   200744 Inﬂ  iximab NA 2003 MTX and prednisone 44 MTX naive
Fleischmann   et al   200845* Certolizumab FAST4WARD 2003 Placebo 220 MTX experienced
Keystone   et al   200846 Certolizumab RAPID1 2005 MTX 982 MTX experienced
Smolen   et al   200847* Certolizumab RAPID2 2005 MTX 619 MTX experienced
Combe   et al   200848* Etanercept 309 2000 SSZ 254 MTX experienced
Emery   et al   200849 Etanercept COMET 2004 MTX 542 MTX naive
Kameda   et al   200850 Etanercept JESMR 2005 MTX 151 MTX experienced
Sheehy   et al   200851 Etanercept NA – MTX 40 MTX naive
Wyeth data on ﬁ  le Etanercept 0881A1-319 2006 MTX 156 MTX experienced
Sennels   et al   200852 Etanercept ADORE 2003 Etanercept 25 MTX experienced
Weinblatt   et al   200853 Etanercept NA 2005 Etanercept 200 MTX experienced
Miyasaka   et al   200854 Adalimumab CHANGE 2004 Placebo 352 MTX experienced
Kay   et al   200855 Golimumab NA 2003 MTX 172 MTX experienced
Keystone 200814 Golimumab GO–FORWARD 2005 MTX 444 MTX experienced
Emery   et al   200915 Golimumab GO–BEFORE 2005 MTX 634 MTX naive
Smolen   et al   200956 Golimumab GO–AFTER 2006 Placebo 461 MTX experienced
      MTX, methotrexate; NA, not available; TNF, tumour necrosis factor.
*Date denotes the ﬁ  rst date of publication (online)       
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considered to be potentially relevant and came to a consensus 
on inclusion based on the inclusion criteria. 
  Data  extraction 
  One reviewer examined all publications for duplication of study 
populations. After removing duplicates, the study characteris-
tics, including study design, patient enrolment dates, baseline 
demographics, clinical characteristics and relevant clinical out-
comes, were recorded for all studies. Publications were also 
identiﬁ  ed as studies having either methotrexate-experienced or 
methotrexate-naive populations. 
  Unpublished study enrolment dates were obtained using 
the study identiﬁ  cation number from follow-up publications, 
ClinicalTrials.gov, fda.gov, Trial Trove, Prous Integrity, Adis 
Clinical Trial and Adis R&D Insight. If study enrolment dates 
were unavailable from these resources, the publication’s pri-
mary authors were contacted to obtain the information. All 
other missing information was noted as not available and was 
not reported in subsequent analyses.   
  Data  analysis 
  We evaluated the inclusion criteria and baseline characteristics of 
the patients from studies over the years. The time point for each 
study was the enrolment start date. The anchor time point was 
the earliest enrolment start date for the ﬁ  rst study. Time points 
for all other studies were measured (in months) from the anchor 
time point. Regression analysis was used to evaluate changes 
in inclusion criteria and baseline characteristics over time. The 
hypothesis of coincidence and equality of intercept was tested 
for the linear models at a signiﬁ  cance level of α<0.05. 
  If baseline descriptive statistics for the total study population 
were not available, a weighted mean was calculated for continu-
ous variables by multiplying the mean value for each study arm 
by the number of patients in the study arm, summing these val-
ues, then dividing by the total number of patients in the study. 
  We conducted a sensitivity analysis to account for missing 
enrolment dates or baseline characteristics. The mean elapsed time 
from enrolment start date to publication date for all studies with 
known values was subtracted from the publication date of studies 
with missing enrolment start dates to obtain an estimated enrol-
ment start date. If the estimated enrolment start date was before 
the anchor enrolment start date, the anchor date was used. 
  Data from primary publications (those with primary end-
points) were used for subsequent analysis and study entry 
  criteria and baseline clinical characteristics were evaluated over 
time for methotrexate-experienced and methotrexate-naive 
study populations using regression analysis.     
  RESULTS 
  A total of 2333 abstracts/manuscripts from MEDLINE, EMBASE, 
the Cochrane Library and other sources (bibliographies from 
health technology assessments, review articles, etc.) were iden-
tiﬁ  ed. Duplicate and extraneous publications from each source 
were removed using Reference Manager, leaving 1407 unique 
manuscripts for etanercept (n=411), adalimumab (n=412), inf-
liximab (n=537), certolizumab (n=38) and golimumab (n=9). 
  Figure 1   shows the results of the ﬁ  ltering process in which pub-
lications were selected for inclusion in the analysis. Of the 1407 
unique publications obtained during the medical literature data-
base search, 1256 were excluded because they were not dou-
ble-blind, randomised, controlled studies, did not include the 
intervention of interest, did not include the population of inter-
est, had less than 4 weeks of follow-up (n=4) or had a sample 
size of fewer than 25 patients. The remaining 151 publications 
were retrieved for detailed evaluation. A total of 1435 abstracts 
were identiﬁ  ed during the ACR and EULAR congress search. 
Of these, 1388 abstracts were excluded because they did not 
provide sufﬁ   cient information, had results that were subse-
quently published in the peer-reviewed literature and included 
in the medical literature database search, were not double-blind, 
randomised, controlled studies; or did not evaluate anti-TNFα 
agents in RA. The remaining 47 abstracts were retrieved for 
more detailed evaluation.       
Studies of anti-TNFα agents 
  A total of 88 double-blind, randomised, controlled studies of anti-
TNFα agents met the inclusion criteria. From these, 44 primary 
publications were identiﬁ  ed that reported the results of a priori 
primary study endpoints, including eight adalimumab studies, 
four certolizumab studies, 17 etanercept studies, ﬁ  ve golimumab 
studies and 10 inﬂ  iximab studies (  table 1  ). Of the primary stud-
ies, 37 were conducted in methotrexate-experienced patient 
populations and seven were conducted in methotrexate-naive 
patient populations. From these, ﬁ  ve studies were identiﬁ  ed that 
provided x-ray data for methotrexate-  experienced patients and 
ﬁ  ve studies provided x-ray data for patients who were metho-
trexate-naive. Time anchors were Elliott   et al    16   (enrolment start 
date August 1993) for   methotrexate-experienced studies, and 
Bathon   et al    22   (enrolment start date May 1997) for methotrexate-
naive studies.   
 Table  2     Changes in inclusion criteria and baseline characteristics over 
time for methotrexate-experienced and methotrexate-naive populations   
 
 No  of 
studies   Intercept   Slope   R   2    p  Value 
Methotrexate-experienced populations
  Swollen joint counts
  Inclusion  criteria
   Base  case 26 7.2 −0.0069 0.02 0.44
   Sensitivity 34 7.6 −0.0109 0.06 0.16
  Baseline  characteristics
   Base  case 20 22.2 −0.0403 0.17 0.06
   Sensitivity 26 23.0 −0.0468 0.29 0.00
  Tender joint counts
  Inclusion  criteria
   Base  case 26 8.6 −0.0098 0.03 0.39
   Sensitivity 34 9.3 −0.0150 0.07 0.12
  Baseline  characteristics
   Base  case 19 29.3 −0.0219 0.02 0.53
   Sensitivity 25 30.9 −0.0335 0.07 0.20
 C-reactive  protein
  Inclusion  criteria          
   Base  case 17 1.9 −0.0019 0.06 0.34
   Sensitivity 21 2.0 −0.0022 0.10 0.16
  Baseline  characteristics
   Base  case 18 4.8 −0.0199 0.27 0.03
   Sensitivity 24 4.6 −0.0182 0.26 0.01
Methotrexate-naive populations  * 
  Swollen joint counts
  Inclusion  criteria 5 10.9 −0.0630 0.88 0.02
  Baseline  characteristics 6 24.3 −0.0974 0.64 0.05
  Tender joint counts
  Inclusion  criteria 5 13.3 −0.0802 0.86 0.02
  Baseline  characteristics 6 31.9 −0.0869 0.21 0.36
 C-reactive  protein
  Inclusion  criteria 5 1.9 −0.0027 0.17 0.49
  Baseline  characteristics 6 3.8 −0.0059 0.12 0.49
      Data from base case and sensitivity analysis are shown.   
    *    Sensitivity analyses were unnecessary because enrolment start dates were available 
for all studies.     
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    Table 2   summarises the changes in inclusion criteria and 
baseline characteristics over time for anti-TNFα studies in 
methotrexate-experienced and methotrexate-naive patient 
populations.   
  In the studies with methotrexate-experienced populations, 
no signiﬁ  cant   difference over time was observed in any inclu-
sion criteria (tender or swollen joint counts or C-reactive protein 
(CRP; ﬁ  gure 2). However, signiﬁ  cant decreases (or trends) over 
time were observed in baseline swollen joint count (p=0.06, 
R  2  =0.17;     ﬁ  gure 2B  ) and CRP (p=0.03, R  2  =0.27;   ﬁ  gure 2F  ), but not 
in baseline tender joint counts (  ﬁ  gure 2D  ). Sensitivity analyses 
conﬁ  rmed the ﬁ  ndings in the base case for each measurement.     
In the studies with methotrexate-naive populations, signiﬁ  -
cant decreases over time were observed in swollen joint inclu-
sion criteria (p=0.02, R  2  =0.88;   ﬁ  gure  3A  ) and mean baseline 
swollen joint count (p=0.05, R  2  = 0.64;   ﬁ  gure 3B  ) and tender joint 
inclusion criteria (p=0.02, R  2  =0.86;   ﬁ  gure 3C  ), but not in baseline 
tender joint count, CRP or CRP inclusion criteria (  ﬁ  gure 3D  –  F  ). 
Sensitivity analyses were unnecessary because enrolment start 
dates were available for all methotrexate-naive studies.
      In the ﬁ  ve studies of methotrexate-experienced patients that 
included x-ray data, the mean baseline Sharp or van der Heijde 
modiﬁ  ed Sharp score decreased signiﬁ  cantly over time (p=0.01, 
R  2  =0.93;   ﬁ  gure  4A  ). Indeed, numerically this difference was 
quite dramatic, accounting for more than a 50% reduction over 
approximately 10 years. There was no signiﬁ  cant decline in the 
mean baseline van der Heijde modiﬁ  ed Sharp score in the  studies 
of methotrexate-naive patients (p=0.90, R  2  =0.01;   ﬁ  gure  4B  ). 
Annual radiographic progression (another measure of disease 
severity) for each of these studies was estimated by dividing the 
mean baseline Sharp or van der Heijde modiﬁ  ed Sharp score by 
the mean disease duration. This estimated progression was then 
 Figure  1     Results of literature search and process of eliminating publications. *two clinical study reports that were included for golimumab. These 
studies have since been published.  14    15   ACR, American College of Rheumatology; DB, double blind; EULAR, European League Against Rheumatism; 
RCT, randomised controlled trial; TNF, Tumour necrosis factor.       
Potentially relevant RCTs identified
from ACR/EULAR Abstracts and 
screened for retrieval
n=1,435 
RCTs retrieved for more 
detailed evaluation
n=47 
Excluded: n=1,388 
Lack of needed information;
duplicate results; 
not DB RCT or intervention 
or population of interest; 
other inclusion/exclusion criteria 
Potentially relevant 2,333 RCTs 
identified from literature search and 
screened for retrieval.
After removing duplicates
n=1,407 
RCTs retrieved for more 
detailed evaluation
n=151 
Primary publications of RCTs reporting the 
results of a priori primary endpoints*
n=44
RCTs excluded after more detailed and full text review
n=110
Excluded: n=1,256 
Not DB RCTs:
Not intervention of interest;
Not population of interest;
<4 weeks duration;
sample size <25 other  
inclusion/exclusion criteria 
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compared with the actual progression observed in the control 
(methotrexate±placebo) group for each of the trials at 52 weeks. 
Comparisons were made for methotrexate-experienced and 
methotrexate-naive studies separately (  ﬁ  gure 5A  ,  B  ). While the 
annualised progression rates did not show a consistent pattern 
over the years, the actual progression observed over 1 year in the 
control groups was much lower than the estimated annualised 
progression rate for the more recent trials. The annualised pro-
gression rate, which predicted progression rate very well in con-
trol groups in older trials like ATTRACT and others,  57    –    60   does 
not seem to predict the progression rate in the control groups at 
all in the more recent trials.         
  DISCUSSION 
  The results of this study show that the characteristics of patients 
who were enrolled in studies of TNFα inhibitors in RA have 
changed over the years. Since 1993, with the ﬁ  rst randomised, 
controlled study of an anti-TNFα agent, disease characteristics 
of patients who participate in these studies have become gen-
erally less severe. Among patients in methotrexate-experienced 
  studies, signiﬁ  cant decreases in baseline swollen joint count and 
CRP were observed. The most dramatic change was seen in base-
line radiographic scores, which decreased by more than 50% 
over just one decade. This change relates to both baseline scores 
and estimated annual progression rates and has been suggested 
by others.  57    –    60   Despite these observations, the determination of 
whether these changes are clinically meaningful is beyond the 
scope of the current study. 
  In line with the decline in swollen joint count and CRP at 
baseline, which are the major variables associated with the pro-
gression of joint damage,  61     62   these data suggest that the stan-
dard of care (for the pool of patients from which clinical trial 
patients are obtained) has improved during the past decade.  63   
The decrease in baseline disease characteristics was less pro-
nounced in the methotrexate-naive (early RA) population than 
the methotrexate-experienced (more established and longer 
standing disease) population, an observation suggesting that 
the general characteristics of RA at presentation may not have 
changed over the years. Methotrexate-naive early RA patients 
may reﬂ  ect the clinical characteristics of RA at presentation/
diagnosis more closely with minimal inﬂ  uence of treatments 
received, whereas the clinical characteristics of more established 
methotrexate-experienced RA patients may be inﬂ  uenced by 
the treatments received. The changes in the clinical characteris-
tics of patients being enrolled in randomised clinical trials may 
thus be more of a function of improved standard of care and 
change in the treatment paradigm of RA (for the pool of patients 
from which clinical trial patients are recruited). However, while 
changes in demographics and general health aspects may con-
tribute to less severe disease,  12   better care for patients with RA 
may be the major reason for this observation.  9   Other possibili-
ties must also be considered; for example, investigative sites are 
 Figure  2     Results for entry criteria and actual mean baseline values in methotrexate-experienced patients over time. CRP, C-reactive protein; SJC, 
swollen joint count; TJC, tender joint count.       
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 Figure  3     Results for entry criteria and actual mean baseline values in methotrexate-naive patients over time. CRP, C-reactive protein; SJC, swollen 
joint count; TJC, tender joint count.       
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 Figure  4     Results for change in mean baseline total Sharp or van der Heijde modiﬁ  ed Sharp score over time (months elapsed since anchor study) for 
(A) Methotrexate-experienced (anchor study 1993) and (B) Methotrexate-naive (anchor study 1997) patients. vdHSS, van der Heijde  Sharp  score.    
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recruiting higher proportions of patients with less severe disease 
to meet the demands of an increased number of clinical trials 
being conducted, the changing geographical distribution of clini-
cal trial sites, etc. However, the current study did not allow for 
the assessment of such possibilities. 
  There are several limitations to our study. First, we focused on 
TNFα inhibitors rather than on all clinical trials performed during 
the time of observation. However, the more recent randomised 
controlled trials for abatacept, rituximab and tocilizumab  64    –    66   
employed the Genant-modiﬁ  ed Sharp score, which has a much 
lower total value than the Sharp or van der Heijde modiﬁ  ed 
Sharp score  64   and, therefore, comparability would be impaired. 
Moreover, the inclusion of data from the studies of newer TNFα 
inhibitors, including certolizumab and golimumab,  14     46     62   ensured 
the integration of studies performed at the same time period as 
these other trials. Second, the number of studies on early RA 
patients was much smaller than on established RA patients 
with inadequate response to methotrexate; consequently, the 
interpretation of these data has to be seen with the respective 
caution. Third, we did not assess publications from registries; 
however, patients evaluated in registries, while constituting ‘real 
life patients’, are of much broader range, do not have to fulﬁ  l 
trial-like inclusion criteria, are dependent on the reimbursement 
status in the individual countries, and are thus more heteroge-
neous. Fourth, the geographic distribution of patients was not 
reported consistently in detail in the manuscripts reviewed. 
 Figure  5     Estimated yearly progression versus actual radiographic progression at week 52 in methotrexate (MTX)-experienced (*actual 1 year 
values in the RAPID2 and GO–FORWARD study were measured at week 24 and extrapolated (doubled) to 1 year) and methotrexate-naive studies 
(*actual radiographic progression (at 1 year) was measured at week 54 in the ASPIRE study and week 52 in all other studies).       
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Although clinical trials are currently being conducted in more 
regions and countries compared with the previous decade, due 
to the unavailability of consistent data from all studies reviewed, 
we were not able to evaluate the change in geographic distribu-
tion of patients in these studies. Fifth, a majority of the studies 
included in these analyses did not provide adequate and con-
sistent data regarding duration of disease, which limited the 
assessment of changes in disease duration of patients enrolled 
in clinical trials over the years. However, the limited data avail-
able to be analysed did not show any speciﬁ  c pattern in disease 
  duration over the years. Disease duration of RA has been shown 
to impact clinical characteristics and responsiveness to treat-
ment by others.  67   Finally, the patient populations studied are 
from randomised clinical   trials; and thus, the changes observed 
over 16 years may reﬂ  ect the changes in patient populations of 
investigative sites looking for patients fulﬁ  lling inclusion criteria 
for clinical trials rather than the entire RA population, at least for 
sites in the US, Canada and western Europe.  63     68   
  Despite the limitations, the trends described above have sev-
eral implications. They suggest that the overall disease char-
acteristics of the population of patients with RA from which 
these subjects are recruited have become less severe over the 
years. During the time period of this study, the standard of care 
(treatment paradigm) of RA has changed, emphasising the ear-
lier diagnosis and earlier and more intensive use of combination 
therapy,  69    70   which results in fewer patients with persistent severe 
disease activity and advanced disability. We also acknowledge 
that trial centres that have limited access to biological therapies 
have improved their therapeutic approaches to RA by virtue of 
the many studies published on the advantage of early and inten-
sive therapy. Indeed, mean methotrexate doses have increased 
when compared with the anchor study,  16   and studies of meth-
otrexate-naive patients have employed much higher doses than 
were used in the anchor study  22   or studies published around the 
same time on leﬂ  unomide trials.  71   In line with this, the results of 
long-term observational studies have suggested that the health 
status of patients with RA has improved.  9     12   
  Whereas multiple factors may be responsible for this change 
in the patient populations enrolled in clinical trials for RA, the 
change in standard of care for RA may be the single most impor-
tant factor. The standard of care now emphasises early intensive 
treatment, and RA patients receive methotrexate earlier and in 
higher doses than patients did more than a decade ago, during 
the clinical trials for etanercept and inﬂ  iximab. The changes in 
the treatment paradigm for RA, coupled with the changes in the 
populations of patients enrolled in clinical trials should be consid-
ered when reviewing new studies on all therapies for RA. These 
changes in the baseline characteristics will also need to be con-
sidered when designing clinical trials in RA. They also have to be 
accounted for when performing meta-analyses of   clinical trials.  72   
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